摘要
目的分析和比较新疆地区醋酸阿比特龙联合泼尼松+雄激素剥夺治疗(ADT)和多西他赛联合泼尼松+雄激素剥夺治疗(ADT)治疗转移性去势抵抗性前列腺癌(mCRPC)的临床疗效和安全性。方法回顾性分析新疆地区7家医院泌尿外科2016年6月至2018年1月收治的mCRPC患者的临床资料。阿比特龙组患者46名,多西他赛组患者48名,观察比较两组临床疗效和安全性的差异。结果中位随访时间15个月。中位影像学无进展生存期(rPFS)阿比特龙组和多西他赛组分别为15个月和11个月,中位前列腺特异性抗原无进展生存期(PSAPFS)阿比特龙组和多西他赛组分别为13个月和9个月。PSA反应率阿比特龙组63.04%,多西他赛组41.67%。在安全性方面,3～5级不良反应的比例阿比特龙组45.65%,多西他赛组47.92%。结论醋酸阿比特龙联合泼尼松+ADT治疗mCRPC相对于多西他赛联合泼尼松+ADT,改善患者rPFS、PSAPFS,提高PSA反应率。在不良反应方面,两种治疗方案无明显差异。
Objective To analyze and compare the clinical efficacy and safety of abiraterone acetate combined with prednisone plus androgen deprivation therapy(ADT)and docetaxel combined with prednisone plus ADT in the treatment of metastatic castration-resistant prostate cancer(mCRPC).Methods The clinical data of mCRPC patients admitted to the urological department of 7 hospitals in Xinjiang during June 2016 and January 2018 were retrospectively analyzed,including 46 patients in the abiraterone group and 48 patients in the docetaxel group.The differences in clinical efficacy and safety were analyzed and compared between the two groups.Results During the median follow-up of 15 months,the median radiographic progression-free survival(rPFS)was 15 months in the abiraterone group and 11 months in the docetaxel group;the median prostate specific antigen progression-free survival(PSAPFS)was 13 months in the abiraterone group and 9 months in the docetaxel group.The PSA response rate was 63.04%in the abiraterone group and 41.67%in the docetaxel group.In terms of safety,the incidence of grade III-V adverse reactions was 45.65%in the abiraterone group and 47.92%in the docetaxel group.Conclusions Compared with docetaxel combined with prednisone plus ADT,abiraterone acetate combined with prednisone plus ADT improved rPFS,PSAPFS and increased PSA response rate.In terms of adverse reactions,there was no significant difference between the two treatment regimens.
作者
冉安鹏
张立东
王玉杰
史振峰
毕兴
吴群
杨军昌
李前跃
邓小虎
何万鹏
王文光
李钊
阿布都克尤木
摆俊博
安恒庆
RAN An-peng;ZHANG Li-dong;WANG Yu-jie;SHI Zhen-feng;BI Xing;WU Qun;YANG Jun-chang;LI Qian-yue;DENG Xiao-hu;HE Wan-peng;WANG Wen-guang;LI Zhao;ABUDUKEYOU-MU;BAI Jun-bo;AN Heng-qing(Urology Center,First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054;Urology Center,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001;Department of Urology,Affiliated Tumor Hospital of Xinjiang Medical University,Urumqi 830011;Department of Urology,Affiliated Hospital of Traditional Chinese Medicine,Xinjiang Medical University,Urumqi 830000;Department of Urology,General Hospital of Xinjiang Military Region,Urumqi 830000;Department of Urology,General Hospital of Xinjiang Production and Construction Corps,Urumqi 830002;Department of Urology,Karamay People's Hospital,Karamay 834000;Postdoctoral Mobile Station of Public Health and Preventive Medicine,Xinjiang Medical University,Urumqi 830054,China)
出处
《现代泌尿外科杂志》
CAS
2019年第4期262-267,共6页
Journal of Modern Urology
基金
新疆维吾尔自治区自然科学基金面上项目(No.2018D01C167)
克拉玛依市科研基金项目(No.JK2016-7)
新疆维吾尔自治区十三五重点学科专项经费(No.2016)
